<p>药明康德（NASDAQ:DXCM - 获取免费报告）在周一发布的报告中，巴克莱的投资分析师将其目标价格从 100.00 美元下调至 80.00 美元，Benzinga 报道。该公司目前对这家医疗设备公司的股票给予 “买入” 评级。巴克莱的目标价格表明该股票的潜在上涨幅度为 24.46%。</p>
<ul>
<li>五月卖出，远离市场——从这三只股票开始</li>
</ul>
<p>其他股票研究分析师也对该股票发布了报告。花旗集团在 5 月 4 日的报告中重新发布了 “买入” 评级，并将药明康德的目标价格下调至 79.00 美元（之前为 84.00 美元）。TD Cowen 在 5 月 1 日的研究报告中将药明康德的目标价格从 84.00 美元下调至 75.00 美元，并对该股票给予 “买入” 评级。瑞穗证券在 5 月 1 日的研究报告中设定了药明康德 75.00 美元的目标价格。雷蒙德·詹姆斯金融在 5 月 1 日的研究报告中设定了药明康德 81.00 美元的目标价格。最后，Evercore 将药明康德的评级从 “持平” 上调至 “跑赢大盘”，并在 3 月 24 日的研究报告中设定了 90.00 美元的目标价格。三位研究分析师对该股票给予了强烈买入评级，十九位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，药明康德目前的平均评级为 “适度买入”，平均目标价格为 82.21 美元。</p>
<p><strong>查看我们关于 DXCM 的最新报告</strong></p>
<h2>药明康德股票表现</h2>
<ul>
<li>分析师喜爱药明康德的三大理由</li>
</ul>
<p>在周一的午盘交易中，药明康德的股票上涨了 2.65 美元，达到了 64.28 美元。该股票的交易量为 5,059,238 股，而其平均交易量为 5,045,384 股。该公司的 50 日移动平均线为 63.46 美元，200 日移动平均线为 65.85 美元。公司市值为 248 亿美元，市盈率为 27.43，市盈增长比率为 1.06，贝塔值为 1.40。药明康德的 52 周低点为 54.11 美元，52 周高点为 89.98 美元。该公司的流动比率为 1.95，速动比率为 1.64，债务与股本比率为 0.42。</p>
<p>药明康德（NASDAQ:DXCM - 获取免费报告）最后一次发布财报是在 4 月 30 日，医疗设备公司报告每股收益（EPS）为 0.56 美元，超出市场共识预期的 0.47 美元，超出幅度为 0.09 美元。该公司在该季度的收入为 11.9 亿美元，而分析师预期为 11.7 亿美元。药明康德的净利润率为 19.31%，股本回报率为 33.33%。该公司的季度收入较去年同期增长了 15.0%。在去年同期，该公司每股收益为 0.32 美元。研究分析师平均预测药明康德在当前年度的每股收益为 2.56 美元。</p>
<h2>内部买卖情况</h2>
<ul>
<li>从分红到增长：为什么这三只股票在 2025 年脱颖而出</li>
</ul>
<p>在其他新闻中，执行副总裁 Michael Jon Brown 在 4 月 15 日的交易中出售了 1,700 股该股票。该股票的平均售价为 63.04 美元，总交易额为 107,168.00 美元。交易完成后，该执行副总裁直接持有公司 111,204 股，价值约为 7,010,300.16 美元。这代表其持股比例下降了 1.51%。该交易已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Bridgette P. Heller 在 5 月 12 日的交易中出售了 1,012 股该股票。该股票的平均售价为 60.01 美元，总价值为 60,730.12 美元。交易完成后，该董事持有公司 25,007 股，价值为 1,500,670.07 美元。这代表其持股比例下降了 3.89%。该销售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在上个季度共出售了 4,412 股公司股票，价值为 278,143 美元。公司内部人士目前持有 0.28% 的公司股票。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近调整了对该公司的持股。佛蒙特信托公司在第四季度将其在药明康德的持股增加了 14.8%。佛蒙特信托公司目前持有 1,122 股医疗设备公司的股票，价值 74,000 美元，此前在上个季度增持了 145 股。CVA 家族办公室在第四季度将其在药明康德的持股增加了 48.5%。CVA 家族办公室目前持有 450 股医疗设备公司的股票，价值 30,000 美元，此前在上个季度增持了 147 股。V Square 定量管理公司在第一季度将其在药明康德的持股增加了 1.8%。V Square 定量管理公司目前持有 9,618 股医疗设备公司的股票，价值 604,000 美元，此前在上个季度增持了 172 股。埃塞克斯金融服务公司在第一季度将其在药明康德的持股增加了 5.7%。埃塞克斯金融服务公司目前持有 3,256 股医疗设备公司的股票，价值 204,000 美元，此前在上个季度增持了 175 股。最后，IFP Advisors Inc 在第三季度将其在药明康德的持股增加了 24.7%。IFP Advisors Inc 目前持有 900 股医疗设备公司的股票，价值 61,000 美元，此前在该期间增持了 178 股。97.75% 的股票目前由机构投资者持有。</p>
<h2>药明康德公司简介</h2>
<p>（获取免费报告）</p>
<p>DexCom, Inc 是一家医疗设备公司，开发、制造和分销用于糖尿病患者的连续血糖监测（CGM）系统。其产品旨在提供近实时的血糖读数、趋势信息和警报，以帮助患者和临床医生管理胰岛素剂量，减少低血糖和高血糖。该公司的产品结合了可穿戴血糖传感器、无线发射器和软件应用，将数据传输到智能手机、专用接收器和基于云的平台，以便进行远程监测。</p>
<p>DexCom 成立于 1999 年，总部位于加利福尼亚州圣地亚哥，专注于推进 CGM 技术，并扩大临床应用，超越传统的胰岛素依赖人群。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 DexCom 更好</li>
<li>为什么 Applied Optoelectronics 的股票可能接近转折点</li>
<li>从高收益到高增长：3 只提升股息的股票</li>
<li>Everspin Technologies 会是下一个 AI 边缘突破吗？</li>
<li>5 只机器人股票值得关注，因为物理 AI 正在蓬勃发展</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 DexCom 吗？</h2>
<p>在考虑 DexCom 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 DexCom 并不在名单上。</p>
<p>虽然 DexCom 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

德康医疗

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>美国银行已将德康医疗（NASDAQ:DXCM）的目标股价从 100.00 美元下调至 80.00 美元，同时维持 “买入” 评级。其他分析师也调整了他们的目标，花旗集团设定的目标为 79.00 美元，TD Cowen 为 75.00 美元。德康医疗的股票目前交易价格为 64.28 美元，较新目标有 24.46% 的上涨潜力。该公司报告每股收益为 0.56 美元，超出预期，市值为 248 亿美元</p>

<p>DexCom (NASDAQ:DXCM - Get Free Report) had its target price reduced by investment analysts at Bank of America from $100.00 to $80.00 in a report issued on Monday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the medical device company's stock. Bank of America's price target points to a potential upside of 24.46% from the stock's current price.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:DXCM - 获取免费报告）在周一发布的报告中，巴克莱的投资分析师将其目标价格从 100.00 美元下调至 80.00 美元，Benzinga 报道。该公司目前对这家医疗设备公司的股票给予 “买入” 评级。巴克莱的目标价格表明该股票的潜在上涨幅度为 24.46%。</p>
</div><ul>
<li>Sell in May and Go Away—Starting With These 3 Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>五月卖出，远离市场——从这三只股票开始</li>
</ul>
</div><p>Other equities research analysts have also issued reports about the stock. Citigroup reissued a &#34;buy&#34; rating and issued a $79.00 target price (down from $84.00) on shares of DexCom in a report on Monday, May 4th. TD Cowen reduced their price objective on shares of DexCom from $84.00 to $75.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, May 1st. Mizuho set a $75.00 price objective on shares of DexCom in a research report on Friday, May 1st. Raymond James Financial set a $81.00 price objective on shares of DexCom in a research report on Friday, May 1st. Finally, Evercore upgraded shares of DexCom from an &#34;in-line&#34; rating to an &#34;outperform&#34; rating and set a $90.00 price objective on the stock in a research report on Tuesday, March 24th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, DexCom presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $82.21.</p>
<div class="lb-trans"><p>其他股票研究分析师也对该股票发布了报告。花旗集团在 5 月 4 日的报告中重新发布了 “买入” 评级，并将药明康德的目标价格下调至 79.00 美元（之前为 84.00 美元）。TD Cowen 在 5 月 1 日的研究报告中将药明康德的目标价格从 84.00 美元下调至 75.00 美元，并对该股票给予 “买入” 评级。瑞穗证券在 5 月 1 日的研究报告中设定了药明康德 75.00 美元的目标价格。雷蒙德·詹姆斯金融在 5 月 1 日的研究报告中设定了药明康德 81.00 美元的目标价格。最后，Evercore 将药明康德的评级从 “持平” 上调至 “跑赢大盘”，并在 3 月 24 日的研究报告中设定了 90.00 美元的目标价格。三位研究分析师对该股票给予了强烈买入评级，十九位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，药明康德目前的平均评级为 “适度买入”，平均目标价格为 82.21 美元。</p>
</div><p><strong>View Our Latest Report on DXCM</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 DXCM 的最新报告</strong></p>
</div><h2>DexCom Stock Performance</h2>
<div class="lb-trans"><h2>药明康德股票表现</h2>
</div><ul>
<li>3 Reasons Analysts Love DexCom</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师喜爱药明康德的三大理由</li>
</ul>
</div><p>DexCom stock traded up $2.65 during midday trading on Monday, hitting $64.28. The stock had a trading volume of 5,059,238 shares, compared to its average volume of 5,045,384. The firm's fifty day moving average is $63.46 and its two-hundred day moving average is $65.85. The company has a market capitalization of $24.80 billion, a PE ratio of 27.43, a P/E/G ratio of 1.06 and a beta of 1.40. DexCom has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.</p>
<div class="lb-trans"><p>在周一的午盘交易中，药明康德的股票上涨了 2.65 美元，达到了 64.28 美元。该股票的交易量为 5,059,238 股，而其平均交易量为 5,045,384 股。该公司的 50 日移动平均线为 63.46 美元，200 日移动平均线为 65.85 美元。公司市值为 248 亿美元，市盈率为 27.43，市盈增长比率为 1.06，贝塔值为 1.40。药明康德的 52 周低点为 54.11 美元，52 周高点为 89.98 美元。该公司的流动比率为 1.95，速动比率为 1.64，债务与股本比率为 0.42。</p>
</div><p>DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm's quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 EPS. On average, research analysts forecast that DexCom will post 2.56 EPS for the current year.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:DXCM - 获取免费报告）最后一次发布财报是在 4 月 30 日，医疗设备公司报告每股收益（EPS）为 0.56 美元，超出市场共识预期的 0.47 美元，超出幅度为 0.09 美元。该公司在该季度的收入为 11.9 亿美元，而分析师预期为 11.7 亿美元。药明康德的净利润率为 19.31%，股本回报率为 33.33%。该公司的季度收入较去年同期增长了 15.0%。在去年同期，该公司每股收益为 0.32 美元。研究分析师平均预测药明康德在当前年度的每股收益为 2.56 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><ul>
<li>From Dividends to Growth: Why These 3 Stocks Stand Out in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>从分红到增长：为什么这三只股票在 2025 年脱颖而出</li>
</ul>
</div><p>In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares in the company, valued at approximately $7,010,300.16. This represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares of the company's stock, valued at $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,412 shares of company stock valued at $278,143 over the last quarter. Corporate insiders own 0.28% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Michael Jon Brown 在 4 月 15 日的交易中出售了 1,700 股该股票。该股票的平均售价为 63.04 美元，总交易额为 107,168.00 美元。交易完成后，该执行副总裁直接持有公司 111,204 股，价值约为 7,010,300.16 美元。这代表其持股比例下降了 1.51%。该交易已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Bridgette P. Heller 在 5 月 12 日的交易中出售了 1,012 股该股票。该股票的平均售价为 60.01 美元，总价值为 60,730.12 美元。交易完成后，该董事持有公司 25,007 股，价值为 1,500,670.07 美元。这代表其持股比例下降了 3.89%。该销售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在上个季度共出售了 4,412 股公司股票，价值为 278,143 美元。公司内部人士目前持有 0.28% 的公司股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the company. Trust Co. of Vermont boosted its position in shares of DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company's stock valued at $74,000 after acquiring an additional 145 shares during the last quarter. CVA Family Office LLC boosted its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock valued at $30,000 after acquiring an additional 147 shares during the last quarter. V Square Quantitative Management LLC boosted its position in shares of DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company's stock valued at $604,000 after acquiring an additional 172 shares during the last quarter. Essex Financial Services Inc. boosted its position in shares of DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company's stock valued at $204,000 after acquiring an additional 175 shares during the last quarter. Finally, IFP Advisors Inc boosted its stake in DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company's stock worth $61,000 after buying an additional 178 shares during the period. 97.75% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近调整了对该公司的持股。佛蒙特信托公司在第四季度将其在药明康德的持股增加了 14.8%。佛蒙特信托公司目前持有 1,122 股医疗设备公司的股票，价值 74,000 美元，此前在上个季度增持了 145 股。CVA 家族办公室在第四季度将其在药明康德的持股增加了 48.5%。CVA 家族办公室目前持有 450 股医疗设备公司的股票，价值 30,000 美元，此前在上个季度增持了 147 股。V Square 定量管理公司在第一季度将其在药明康德的持股增加了 1.8%。V Square 定量管理公司目前持有 9,618 股医疗设备公司的股票，价值 604,000 美元，此前在上个季度增持了 172 股。埃塞克斯金融服务公司在第一季度将其在药明康德的持股增加了 5.7%。埃塞克斯金融服务公司目前持有 3,256 股医疗设备公司的股票，价值 204,000 美元，此前在上个季度增持了 175 股。最后，IFP Advisors Inc 在第三季度将其在药明康德的持股增加了 24.7%。IFP Advisors Inc 目前持有 900 股医疗设备公司的股票，价值 61,000 美元，此前在该期间增持了 178 股。97.75% 的股票目前由机构投资者持有。</p>
</div><h2>DexCom Company Profile</h2>
<div class="lb-trans"><h2>药明康德公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.</p>
<div class="lb-trans"><p>DexCom, Inc 是一家医疗设备公司，开发、制造和分销用于糖尿病患者的连续血糖监测（CGM）系统。其产品旨在提供近实时的血糖读数、趋势信息和警报，以帮助患者和临床医生管理胰岛素剂量，减少低血糖和高血糖。该公司的产品结合了可穿戴血糖传感器、无线发射器和软件应用，将数据传输到智能手机、专用接收器和基于云的平台，以便进行远程监测。</p>
</div><p>Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.</p>
<div class="lb-trans"><p>DexCom 成立于 1999 年，总部位于加利福尼亚州圣地亚哥，专注于推进 CGM 技术，并扩大临床应用，超越传统的胰岛素依赖人群。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than DexCom</li>
<li>Why Applied Optoelectronics Stock May Be Near a Turning Point</li>
<li>From High-Yield to High-Growth: 3 Stocks Boosting Dividends</li>
<li>Is Everspin Technologies the Next AI Edge Breakout?</li>
<li>5 Robotics Stocks to Watch as Physical AI Builds Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 DexCom 更好</li>
<li>为什么 Applied Optoelectronics 的股票可能接近转折点</li>
<li>从高收益到高增长：3 只提升股息的股票</li>
<li>Everspin Technologies 会是下一个 AI 边缘突破吗？</li>
<li>5 只机器人股票值得关注，因为物理 AI 正在蓬勃发展</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=DXCM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DexCom Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 DexCom 吗？</h2>
</div><p>Before you consider DexCom, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 DexCom 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 DexCom 并不在名单上。</p>
</div><p>While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 DexCom 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bank of America Lowers DexCom (NASDAQ:DXCM) Price Target to $80.00

Market Beat

2 倍做多纳斯达克生物技术 ETF - ProShares

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

美国银行

花旗

瑞穗金融集团

Mizuho Financial Group, Inc.

瑞杰金融

Evercore

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

美国银行将德康医疗（NASDAQ:DXCM）的目标股价下调至 80 美元